Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656019 · ClinicalTrials.gov registry record · Phase 2
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00656019: Completed Phase 2 study, sponsored by Stanford University.
NCT00656019 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00656019, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study will assess whether levels of vitamin D impact the characteristics of a woman's breast cancer at diagnosis, and whether a short course of vitamin D in women with low levels of vitamin D changes the gene expression of their breast cancers.
Interventions
- DRUG Vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656019
The ClinicalTrials.gov registry entry for NCT00656019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vitamin D is the first listed.
NCT00656019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656019 about?
NCT00656019 is a clinical study titled "Development of Vitamin D as a Therapy for Breast Cancer - Phase 2". This study will assess whether levels of vitamin D impact the characteristics of a woman's breast cancer at diagnosis, and whether a short course of vitamin D in women with low levels of vitamin D changes the gene expression of their breast cancers.
What is the current status of trial NCT00656019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2008-04. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00656019?
The interventions under investigation include: Vitamin D (DRUG).
Who is sponsoring clinical trial NCT00656019?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.